Maxcyte (MXCT) Asset Writedowns and Impairment (2023 - 2026)

Maxcyte (MXCT) has reported Asset Writedowns and Impairment for 4 consecutive years, with $630000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $630000.0 in Q2 2026; TTM through Jun 2026 was $1.3 million, a 21.25% decrease from a year earlier, with the FY2025 full-year figure at $676000.0, down 61.83% from the prior year.
• Asset Writedowns and Impairment was $630000.0 for Q2 2026 at Maxcyte, up from $197000.0 in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $937000.0 in Q4 2024 and troughed at -$9000.0 in Q3 2023.
• A 4-year average of $331000.0 and a median of $197000.0 in 2026 frame the typical range for Asset Writedowns and Impairment.
• Across the five-year window, Asset Writedowns and Impairment surged 7844.44% in 2024 and slumped 83.88% in 2025, its largest moves.
• Over 4 years, Asset Writedowns and Impairment stood at $476000.0 in 2023, then surged by 96.85% to $937000.0 in 2024, then tumbled by 83.88% to $151000.0 in 2025, then jumped by 317.22% to $630000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $630000.0 (Q2 2026), $197000.0 (Q1 2026), and $151000.0 (Q4 2025), per Business Quant data.